Medical Director Warns of Cell Phone Risks
Posted on: Wednesday, 23 July 2008, 18:00 CDT
The director of a Pittsburgh health complex is distributing an advisory to employees on avoiding possible health risks associated with cell phone use.
Among suggestions Dr. Ronald Herberman listed to limit exposure to electromagnetic radiation emitted by the devices were texting, shortening conversations and using headset or speaker phone options, the Pittsburgh Post-Gazette reported Wednesday.
Recently I have become aware of the growing body of literature linking long-term cell phone use to possible adverse health effects, including cancer, Dr. Ronald Herberman told faculty and staff at the Pittsburgh Cancer Institute and the University of Pittsburgh Medical Center. Although the evidence is still controversial, I am convinced that there are sufficient data to warrant issuing an advisory to share some precautionary advice on cell phone use.
Herberman said other countries have recommended limits on exposure, and public health officials in Toronto have advised young people to limit cell phone use.
While support for limited cell phone use may be growing, it isn't universal, the newspaper said.
Precautions are good, but the bottom line, at this time, is that there is no conclusive evidence tying cell phone use to brain cancer, said Dan Catena, an American Cancer Society spokesman.
Source: United Press International
Related Articles
- Cell Phones and Cancer: More Research Needed
- IGI Laboratories, Inc. Signs Product Development Agreement With Cancer Health Solutions Resources, LLC
- Verizon Wireless Activates New Cell Site in Pittsburgh
- Verizon Wireless Activates New Cell Site in Pittsburgh
- ZymoGenetics Initiates Phase II Renal Cell Cancer Trial
- ZymoGenetics Begins Phase 2 Trial in Renal Cell Cancer Evaluating IL-21 Combined With Nexavar(R)
- Two in Three Believe Radiation From Phones Damaged Their Health
- Cytokinetics Announces Initiation of Phase II Clinical Trial in Renal Cell Cancer and Phase I Clinical Trial in Pediatric Solid Tumors
- ZymoGenetics Begins Phase 1/2 Clinical Trial With IL-21 and Nexavar in Patients With Renal Cell Cancer
- New In Vitro Study of GlycoGenesys' GCS-100LE Yields Promising Data in Chronic Lymphocytic Leukemia and Other B-Cell Cancers
User Comments (0)

RSS Feeds